In this panel companies discuss developments in the broader market, as well as their unique late-stage drugs looking to address cardiac-based indications.

Panelists include Quang Pham, Chairman & CEO at Cadrenal Therapeutics and Craig Fraser, CEO at Windtree Therapeutics, Inc.

This KOL Panel was recorded during the Lytham Partners Fall 2023 Investor Conference.